Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Trillium gets a buyout while it's down
The latest deal over a CD47 asset has got investors wondering who could be next.
“Don’t eat me” competition finds Celgene discontinuation hard to digest
Celgene’s surprise termination of a clinical trial makes for a day of soul-searching among other followers of the anti-CD47 approach.